SEQUENTIAL COMPRESSION DEVICE SALES BUSINESS PLAN

I. Executive Summary

Company Description

CircuGuard Medical, Inc.—named for circulation protection—operates in the U.S. medical-device sector supplying FDA-cleared pneumatic compression therapy devices that prevent life-threatening blood clots. We sell to clinical and home-care markets and combine engineered devices with a direct-to-patient support model. Our competitive edge is a lean manufacturing and distribution setup that reduces lead time, plus a patient-support team that drives adherence and clinical outcomes. One line: We deliver FDA-cleared compression devices with lean supply and hands-on patient support.

Core activities include in-house assembly, quality and regulatory compliance, centralized warehousing at our U.S. headquarters, clinical partnerships for trials and referrals, and direct shipping plus telehealth onboarding for home patients. Target customers are hospitals, surgical centers, post-acute providers, and at-risk home-care patients (post-op and elderly). Short-term goals: launch in 2026, deploy 5,000 devices in year one, and secure three national distributor contracts. Long-term goals: scale to 50,000 devices/year, reach nationwide coverage within 36 months, and achieve sustained EBITDA profitability by year three. One line: We scale fast from launch to nationwide coverage while keeping quality and compliance central.

Problem

Annually, hundreds of thousands of Americans develop preventable blood clots such as deep vein thrombosis (DVT) after orthopedic surgery or during extended immobility, increasing risk of pulmonary embolism, healthcare costs, and mortality.

Current post-discharge prophylactic options lack portability and ease of use, producing low patient adherence, higher readmission and complication costs, and a gap in effective at-home care; there is a clear need for portable, hospital-grade at-home prophylaxis.

We address that gap with FDA-cleared pneumatic compression therapy devices and a direct-to-patient support model, launching in 2026 to deliver portable, hospital-grade prophylaxis for clinical and home-care markets.

Solution

Each year hundreds of thousands of Americans suffer preventable Deep Vein Thrombosis (DVT) and related complications after surgery or during immobility, generating high mortality and billions of dollars in avoidable healthcare costs. Existing devices are often too bulky for home use or lack support for patient compliance, leaving a gap between hospital prophylaxis and safe home recovery.

We offer an FDA-cleared line of sequential compression devices: a clinical-grade Pro System for hospitals and a portable, battery-operated Home model for patient-led recovery. Both replicate natural blood flow via timed sequential inflation, pair with comprehensive education to boost adherence, and provide a portable hospital-grade solution that bridges clinical care to home recovery. One line: clinical power, home portability, continuity of prophylaxis.

Mission Statement

Our mission is to eliminate preventable blood clots by making advanced hospital-grade compression therapy accessible and easy to manage for every patient. We are committed to improving circulatory health and reducing healthcare costs through innovation, education, and superior customer support. We empower patients in recovery and give healthcare professionals the most reliable tools for DVT prophylaxis while upholding clinical excellence and regulatory integrity. By 2030 we aim to be the gold standard in portable pneumatic therapy across the United States.

Key Success Factors

These factors determine market access, margins, and clinical adoption for the Sequential Compression Device business.

• FDA 510(k) clearance and ongoing compliance with Quality Management System regulations ensure regulatory market access.
• Scaling sales force to 15 reps by 2030 to secure large hospital and GPO contracts.
• Low COGS (11%→9%) to sustain strong gross margins and competitive pricing.
• Rapid economics: 2-month breakeven and 11-month payback proving financial efficiency.
• Comprehensive patient education and support driving high compliance and clinical success.

Financial Summary

Brief financial snapshot for the Executive Summary: launch in 2026 with rapid revenue and EBITDA growth through 2030.

The plan requires maintaining a minimum operating cash buffer of $805,000 (minimum cash month: Feb-26) to support product launch, manufacturing capex, and working capital; the model targets a five-year IRR of 24.42%.

Financial outlook: strong recurring revenue from disposable garment packs and disciplined cash management drive a high-return growth path.

Funding Requirements

We seek $1,180,000 to launch in 2026; forecasts show 2026 revenue of $2,323,000, 2026 EBITDA of $632,000, a five-year IRR of 24.42%, and a required minimum cash reserve of $805,000.